home > news > detailed info

BioIVT to Focus on the Application of In Vitro Hepatocyte Models in Toxicology Research at the North American ISSX Meeting

Research using BioIVT’s TRANSPORTER CERTIFIED™ hepatocytes in sandwich culture and HEPATOPAC® technology in vitro liver models will be presented.

BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrčs de Montréal in Montréal, Canada.


ISSX is one of the largest scientific societies dedicated to investigating the metabolism and disposition of chemicals in biological systems. As a result, its activities are relevant to all aspects of drug development and toxicology.


“Biopharmaceutical companies want to conduct toxicology studies as early as possible in their drug development programs so that they can identify candidates that are going to have safety issues during the preclinical phase,” said Kenneth Brouwer, PhD, RPh, vice president, ADME-Tox at BioIVT. “We welcome this opportunity to support ISSX and highlight some of the promising toxicology research being conducted using our HEPATOPAC technology, TRANSPORTER CERTIFIED hepatocytes, and ADMET PHASEZERO® Research Services.”


BioIVT’s HEPATOPAC technology is used to create stable in vitro liver models that permit long-term hepatic metabolism and toxicity studies.


The company’s TRANSPORTER CERTIFIED hepatocytes, when cultured in sandwich culture, closely reflect physiologic conditions because the hepatocytes express functioning uptake and efflux transporters and develop bile pockets similar to bile canaliculi.


BioIVT’s PHASEZERO Research Services team works collaboratively with clients, providing expertise and guidance to help advance their drug development programs. BioIVT’s ADME Tox scientists design and implement programs to address clients’ liver-related research questions. With a broad portfolio of hepatic products and technologies, and extensive experience, BioIVT recommends comprehensive research programs customized to meet clients’ objectives and the characteristics of their compounds.


BioIVT is participating in the following ISSX sessions:


Monday, July 16


1:30-2:00 pm

Jonathan Jackson, PhD, BioIVT study director, will present poster #P50 entitled “An Integrated In Vitro Screen Using Sandwich-cultured Human Hepatocytes for Prediction of Cholestatic Hepatotoxicity.”


Tuesday, July 17

Industry-sponsored Symposium

7:30-8:30 am

BioIVT is sponsoring the symposium entitled “Applications of a Micropatterned Co-cultured Hepatocyte System to Support Small Molecule Drug Discovery” presented by T. Eric Ballard, PhD, principal scientist in the Biotransformation Group in Pharmacokinetics, Dynamics, and Metabolism at Pfizer.



2:30-5:00 pm

Scott Heyward, PhD, BioIVT director, research and development and scientific affairs, will give the opening remarks at the 14th Annual Assembly of the Hepatocyte Research Association. This year’s meeting, which addresses “P450 Enzyme Induction: A Deeper Dive,” will explore how human and animal hepatocytes communicate with each other. It will also provide attendees with practical information about using hepatocytes in their research.


In addition, BioIVT PHASEZERO Research Services consultants will be available to answer technical questions about the company’s toxicology research products and services in booth #407.


For further information about the North American ISSX Meeting, please visit


About BioIVT


BioIVT, formerly BioreclamationIVT, is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.comor follow the company on Twitter @BioIVT.

Print this page
Send to a friend
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement